Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to se

Social Author Image

https://pbs.twimg.com/profile_images/956713613854584833/7Vo7a2l5_normal.jpg

Tweet Author

Social Author Name

Mike Putman

Tweet Content

Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to see focus on PROs & I always love a good spidergram @RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to se

Do you get our email newsletter?